skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Enavatuzumab (Code C80045)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Enavatuzumab

Definition: A humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. Enavatuzumab binds to TWEAKR and inhibits TWEAK ligand binding and activation of NF-kappaB-mediated cytokine release, which may result in tumor cell apoptosis. TWEAKR is a cell-surface receptor with homology to tumor necrosis factor receptors. Upon binding with its ligand, TWEAKR has been shown to stimulate cytokine release and cell proliferation, migration, and survival; it may also promote apoptosis under some conditions. This receptor may be overexpressed in a variety of tumors including those of the pancreas, colon, lung, kidney, and breast.

Display Name: Enavatuzumab

Label: Enavatuzumab

NCI Thesaurus Code: C80045 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2698154  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-tumor Necrosis Factor-like Weak Inducer of Apoptosis Monoclonal Antibody PDL192
PDL 192

External Source Codes: 
CAS Registry Number 1062149-33-0 (see NLM ChemIDplus info)
FDA UNII Code 914910XFBB
PDQ Closed Trial Search ID 613893
PDQ Open Trial Search ID 613893 (check for NCI PDQ open clinical trial info)
UMLS CUI C2698154

Other Properties:
     Name Value (qualifiers indented underneath)
code C80045
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Anti-TWEAKR_Monoclonal_Antibody_PDL192
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom